Leber congenital amaurosis is an IRD caused by a defect in the CEP20 gene, resulting in progressive vision loss in infants. Two new agents that target the CEP20 gene are currently in clinical trials:
The BRILLIANCE phase 1/2 clinical trial is investigating gene-editing techniques using CRISPR-Cas9 to delete the mutation in the CEP290 gene that is responsible for destroying light-sensing cells in the retina.
Phase 2/3 clinical trials by ProQR Therapeutics is testing RNA antisense oligonucleotide gene therapy. Results have demonstrated significant improvement in vision several months after injection.
Learn more about inherited retinal diseases.
Editor's Recommendations
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Donny W. Suh. Fast Five Quiz: Management of Inherited Retinal Diseases - Medscape - Apr 27, 2022.
Comments